Mubadala Capital partners with Ardian on landmark transaction
In April 2017, Mubadala Capital and Ardian, an independent investment company with US $60 billion of assets under management, completed a private equity transaction which saw Ardian commit US $2.5 billion across two newly created private equity funds to be managed by Mubadala Capital.
The transaction included Ardian acquiring a majority interest in an existing pool of private equity assets as well as making a new Limited Partners (LP) commitment alongside Mubadala to a US $1.5 billion private equity fund, which is currently being invested.
Subsequent to the initial closing, Mubadala and Ardian conducted a syndication process which resulted in an additional 13 institutional LPs participating in the transaction. The combination of the secondary component and the new LP commitment makes this transaction the largest secondary staple deal ever completed.
The secondary portfolio was comprised of an existing pool of Mubadala Capital owned and managed private equity assets that included 14 LP interests in predominantly North American buyout and growth funds, and 14 direct investments, including a number of co-investments alongside renowned GPs.
The new primary capital is being invested following the same strategy that built the secondary portfolio, which involves an integrated approach to making direct investments, co-investments and fund commitments, primarily in North America and Europe. The focus continues to be on partnering with best-in-class management and investment teams across multiple sectors, including sports, media, entertainment, consumer, energy infrastructure, light industrials, non-balance sheet financial services and others.
This transaction marked the first time Mubadala Capital accepted capital from third party investors, which the group views as a significant milestone in the continued growth and development of the asset management business and a strong endorsement of Mubadala Capital’s investment track record to date.
Cleveland Clinic Abu Dhabi’s First Comprehensive Organ Transplant Program
Cleveland Clinic Abu Dhabi (CCAD), part of Mubadala’s network of world-class healthcare providers, is a multispecialty hospital designed to address a range of complex and critical care requirements unique to the Abu Dhabi population. The facilities combine state-of -the-art amenities and world-class service standards, providing patients in the region direct access to the world’s best healthcare providers and Cleveland Clinic’s unique model of care, reducing their need to travel abroad for treatment.
The depth and breadth of the hospital was demonstrated in 2017, as CCAD became the UAE’s first and only multi-organ transplant facility, following the UAE government’s decree allowing deceased donor transplants.
A CCAD four-person surgical team performed the UAE’s first full heart transplant in December 2017. On the same night, the hospital performed a kidney transplant from the same donor, providing vital surgery for another patient on the hospital’s transplant list.
Months before this major milestone, on September 2017, the hospital successfully conducted one of the UAE’s first kidney transplants from a deceased donor as well.
CCAD has worked diligently with the Cleveland Clinic Transplant Center in the US, a world leader in organ transplantation; partner hospitals in the UAE; and the Saudi Center for Organ Transplant (SCOT) in establishing its organ transplant program. The transplant program has also benefitted from continued collaboration with Abu Dhabi Police and a number of other government entities.
As wider pool of potential donors are engaged, transplants can be conducted more rapidly for the seriously ill. Through this program and by cooperating with key partners and multiple facilities across the region, tremendous positive impact within the UAE has been achieved thus far.
As wider pool of potential donors are engaged, transplants can be conducted more rapidly for the seriously ill.